BIONOTE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,080 KRW | 0.00% |
|
-0.24% | -3.89% |
| 2023 | BioNote, Inc.(KOSE:A377740) added to S&P Global BMI Index | CI |
| 2023 | SD Biosensor, Inc announced that it has received KRW 226.0893359 billion in funding from BioNote, Inc. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 480B 350M | Sales 2023 | 90.08B 65.76M | Capitalization | 433B 316M |
|---|---|---|---|---|---|
| Net income 2022 | 308B 225M | Net income 2023 | -20.5B -14.96M | EV / Sales 2022 | 0.32 x |
| Net cash position 2022 | 720B 526M | Net cash position 2023 | 395B 289M | EV / Sales 2023 | 0.42 x |
| P/E ratio 2022 |
2.63
x | P/E ratio 2023 |
-21.1
x | Employees | 313 |
| Yield 2022 |
5.71% | Yield 2023 |
4.71% | Free-Float | 14.67% |
More Fundamentals
* Assessed data
More news
| 1 week | -0.24% | ||
| Current month | -0.85% | ||
| 1 month | +0.74% | ||
| 3 months | -8.83% | ||
| 6 months | +0.74% | ||
| Current year | -3.89% |
1 week
4 045.00
4 160.00
1 month
3 895.004 160.00
Current year
3 865.004 820.00
1 year
3 800.006 460.00
3 years
3 800.0011 700.00
5 years
3 800.0011 700.00
10 years
3 800.0011 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Sik Cho
CHM | Chairman | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Sik Cho
CHM | Chairman | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 4,080 | 0.00% | 40,676 |
| 24-05-09 | 4,080 | -0.12% | 31,009 |
| 24-05-08 | 4,085 | -0.24% | 27,444 |
| 24-05-07 | 4,095 | -0.12% | 63,894 |
| 24-05-03 | 4,100 | +0.24% | 50,724 |
End-of-day quote Korea S.E., May 09, 2024
More quotes
BioNote Inc is a Korea-based company mainly engaged in the bio-contents business. The Company is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The Company is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.89% | 304M | |
| -4.84% | 182B | |
| +0.56% | 110B | |
| -3.35% | 68.11B | |
| +2.39% | 50.53B | |
| +9.36% | 44.8B | |
| +2.70% | 40.7B | |
| +24.51% | 32.3B | |
| +3.43% | 26.53B | |
| +13.67% | 25.02B |
- Stock Market
- Equities
- A377740 Stock